BidaskClub lowered shares of Sangamo Therapeutics (NASDAQ:SGMO) from a strong-buy rating to a buy rating in a research report report published on Saturday morning.
SGMO has been the subject of several other research reports. Wedbush reissued a hold rating and issued a $8.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, March 13th. Barclays reissued a buy rating and issued a $30.00 price target on shares of Sangamo Therapeutics in a research note on Sunday, February 25th. Jefferies Group reissued a buy rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. Zacks Investment Research cut Sangamo Therapeutics from a buy rating to a hold rating in a research note on Friday, January 5th. Finally, Piper Jaffray Companies set a $25.00 price target on Sangamo Therapeutics and gave the company a buy rating in a research note on Wednesday, January 3rd. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $20.83.
Sangamo Therapeutics (NASDAQ:SGMO) opened at $24.10 on Friday. Sangamo Therapeutics has a fifty-two week low of $3.85 and a fifty-two week high of $27.50. The company has a debt-to-equity ratio of 0.13, a current ratio of 5.54 and a quick ratio of 5.54. The stock has a market capitalization of $2,028.97, a PE ratio of -34.43 and a beta of 2.60.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. Sangamo Therapeutics had a negative return on equity of 31.44% and a negative net margin of 149.23%. The business had revenue of $13.08 million during the quarter, compared to analysts’ expectations of $11.10 million. During the same quarter in the prior year, the firm earned ($0.14) EPS. The business’s revenue for the quarter was up 46.6% compared to the same quarter last year. equities analysts forecast that Sangamo Therapeutics will post -0.15 earnings per share for the current year.
In related news, VP Edward R. Conner sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $17.11, for a total transaction of $85,550.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Curt A. Herberts III sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $17.26, for a total value of $258,900.00. Following the sale, the vice president now directly owns 13,015 shares of the company’s stock, valued at approximately $224,638.90. The disclosure for this sale can be found here. In the last three months, insiders sold 95,403 shares of company stock valued at $2,035,169. Insiders own 5.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Xact Kapitalforvaltning AB acquired a new stake in Sangamo Therapeutics during the fourth quarter worth approximately $175,000. MetLife Investment Advisors LLC acquired a new stake in Sangamo Therapeutics during the fourth quarter worth approximately $643,000. Macquarie Group Ltd. grew its stake in Sangamo Therapeutics by 1,016.7% during the fourth quarter. Macquarie Group Ltd. now owns 20,100 shares of the biopharmaceutical company’s stock worth $330,000 after purchasing an additional 18,300 shares during the period. Ladenburg Thalmann Financial Services Inc. grew its stake in Sangamo Therapeutics by 70.0% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 19,189 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 7,900 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. acquired a new stake in Sangamo Therapeutics during the fourth quarter worth approximately $707,000. 64.68% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/21/sangamo-therapeutics-sgmo-stock-rating-lowered-by-bidaskclub.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.